Inpharma Weekly

, Volume 971, Issue 1, pp 13–14 | Cite as

TB or not TB? - Rifater® may be the answer

  • Jo Barnes
Newsletter Article

&

Tuberculosis is once again top of the list of killer infectious diseases in adults throughout the world. Of particular concern is the rise in the incidence of multidrug-resistant strains of Mycobacterium tuberculosis

One approach to reducing the development of multidrug-resistant TB may lie in improving patient compliance. In answer to this, Marion Merrell Dow has recently launched Rifater® in the US, the only triple combination therapy for the treatment of active TB.

Keywords

Rifampicin Isoniazid Pyrazinamide Rifamycin Improve Patient Compliance 

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Jo Barnes

There are no affiliations available

Personalised recommendations